TRENTON, N.J. - A New Jersey appeals panel on June 13 affirmed several pretrial rulings in the state's first Aredia/Zometa jaw injury trial, including one that direct-to-consumer advertising by defendant Novartis Pharmaceuticals Corp. did not trigger New Jersey's exception to the learned intermediary defense (Jane Bessemer, et al. v. Novartis Pharmaceuticals Corporation, No. A-2069-10T1, N.J. Super., App. Div.). Follow this link to review the full Mealey's Legal News Bulletin.